Buzibye A, Musaazi J, Von Braun A, Nanzigu S, Sekaggya-Wiltshire C, Kambugu A, et al. Antiretroviral concentration measurements as an additional tool to manage virologic failure in resource limited settings: a case control study. AIDS Res Ther. 2019;16:39. https://doi.org/10.1186/s12981-019-0255-x.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Donnell D, Baeten JM, Bumpus NN, Brantley J, Bangsberg DR, Haberer JE, et al. HIV protective efficacy and correlates of Tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention. J Acquir Immune Defic Syndr 1999. 2014;66(3):340–48. https://doi.org/10.1097/QAI.0000000000000172.

Kimulwo MJ, Okendo J, Aman RA, Ogutu BR, Kokwaro GO, Ochieng DJ, et al. Plasma nevirapine concentrations predict virological and adherence failure in Kenyan HIV-1 infected patients with extensive antiretroviral treatment exposure. PLoS One. 2017;12(2):e0172960. https://doi.org/10.1371/journal.pone.0172960.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gardner EM, Burman WJ, Steiner JF, Anderson PL, Bangsberg DR. Antiretroviral medication adherence and the development of class-specific antiretroviral resistance. AIDS. 2009;23(9):1035–46. https://doi.org/10.1097/QAD.0b013e32832ba8ec.

Article  PubMed  Google Scholar 

Moltó J, Blanco A, Miranda C, Miranda J, Puig J, Valle M, et al. Variability in non-nucleoside reverse transcriptase and protease inhibitor concentrations among HIV-infected adults in routine clinical practice. Br J Clin Pharmacol. 2006;62(5):560–6. https://doi.org/10.1111/j.1365-2125.2006.02694.x.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Perrone V, Cattaneo D, Radice S, Sangiorgi D, Federici AB, Gismondo MR, et al. Impact of therapeutic drug monitoring of antiretroviral drugs in routine clinical management of patients infected with human immunodeficiency virus and related health care costs: a real-life study in a large cohort of patients. Clin Outcomes Res. 2014;6(1):341–8. https://doi.org/10.2147/CEOR.S58036.

Article  Google Scholar 

Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV | Considerations for Antiretroviral Use in People With Coinfections | Tuberculosis/HIV Coinfection. https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescentarv/tuberculosishiv-coinfection. Accessed 19 Jul 2024.

Cattaneo D, Baldelli S, Cozzi V, Clementi E, Marriott DJE, Gervasoni C, et al. Impact of therapeutic drug monitoring of antiretroviral drugs in routine clinical management of people living with HIV: a narrative review. Ther Drug Monit. 2020;42(1):64. https://doi.org/10.1097/FTD.0000000000000684.

Article  PubMed  Google Scholar 

Gilbert EM, Darin KM, Scarsi KK, McLaughlin MM. Antiretroviral pharmacokinetics in pregnant women. Pharmacother J Hum Pharmacol Drug Ther. 2015;35(9):838–55. https://doi.org/10.1002/phar.1626.

Article  Google Scholar 

Waalewijn H, Turkova A, Rakhmanina N, Cressey TR, Penazzato M, Colbers A, et al. Optimizing pediatric dosing recommendations and treatment management of antiretroviral drugs using therapeutic drug monitoring data in children living with HIV. Ther Drug Monit. 2019;41(4):431–43. https://doi.org/10.1097/FTD.0000000000000637.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sethi AK, Celentano DD, Gange SJ, Moore RD, Gallant JE. Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance. Clin Infect Dis. 2003;37(8):1112–8. https://doi.org/10.1086/378301.

Tchakoute CT, Rhee SY, Hare CB, Shafer RW, Sainani K. Adherence to contemporary antiretroviral treatment regimens and impact on immunological and virologic outcomes in a US healthcare system. PLoS One. 2022;17(2):e0263742. https://doi.org/10.1371/journal.pone.0263742.

Article  CAS  Google Scholar 

Nair G, Celum C, Szydlo D, Brown ER, Akello CA, Nakalega R, et al. Adherence, safety, and choice of the monthly dapivirine vaginal ring or oral emtricitabine plus tenofovir disoproxil fumarate for HIV preexposure prophylaxis among African adolescent girls and young women: a randomised, open-label, crossover trial. Lancet HIV. 2023;10(12):e779–89. https://doi.org/10.1016/S2352-3018(23)00227-8.

Article  CAS  PubMed  Google Scholar 

Roberts ST, Mancuso N, Williams K, Nabunya HK, Mposula H, Mugocha C, et al. How a menu of adherence support strategies facilitated high adherence to HIV prevention products among adolescent girls and young women in sub-Saharan Africa: a mixed methods analysis. J Int AIDS Soc. 2023;26(11):e26189. https://doi.org/10.1002/jia2.26189.

Article  PubMed  PubMed Central  Google Scholar 

Spinelli MA, Haberer JE, Chai PR, Castillo-Mancilla J, Anderson PL, Gandhi M. Approaches to objectively measure antiretroviral medication adherence and drive adherence interventions. Curr HIV/AIDS Rep. 2020;17(4):301–14. https://doi.org/10.1007/s11904-020-00502-5.

Article  PubMed  PubMed Central  Google Scholar 

Gandhi M, Bacchetti P, Rodrigues WC, Spinelli M, Koss CA, Drain PK, et al. Development and validation of an immunoassay for Tenofovir in urine as a real-time metric of antiretroviral adherence. EClinicalMedicine. 2018;31(2–3):22–8. https://doi.org/10.1016/j.eclinm.2018.08.004.

Article  Google Scholar 

Gandhi M, Bacchetti P, Spinelli MA, Okochi H, Baeten JM, Siriprakaisil O, et al. Validation of a urine Tenofovir immunoassay for adherence monitoring to PrEP and ART and establishing the cutoff for a point-of-care test. J Acquir Immune Defic Syndr. 2019;81(1):72–7. https://doi.org/10.1097/QAI.0000000000001971.

Article  PubMed  PubMed Central  Google Scholar 

Pratt GW, Fan A, Melakeberhan B, Klapperich CM. A competitive lateral flow assay for the detection of Tenofovir. Anal Chim Acta. 2018;1017:34–40. https://doi.org/10.1016/j.aca.2018.02.039.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sevenler D, Bardon A, Fernandez Suarez M, Marshall L, Toner M, Drain PK, et al. Immunoassay for HIV drug metabolites Tenofovir and Tenofovir diphosphate. ACS Infect Dis. 2020;6(7):1635–42. https://doi.org/10.1093/JAC/DKAB487.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gandhi M, Glidden DV, Chakravarty D, Wang G, Biwott C, Mogere P, et al. Impact of a point-of-care urine tenofovir assay on adherence to HIV pre-exposure prophylaxis among women in Kenya: a randomised pilot trial. Lancet HIV. 2024;11:e522–30. https://doi.org/10.1016/S2352-3018(24)00125-5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hermans LE, Umunnakwe CN, Lalla-Edward ST, Hebel SK, Tempelman HA, Nijhuis M, et al. Point-of-care tenofovir urine testing for the prediction of treatment failure and drug resistance during initial treatment for human immunodeficiency virus type 1 (HIV-1) infection. Clin Infect Dis. 2023;76(3):e553–60. https://doi.org/10.1093/cid/ciac755.

Article  CAS  PubMed  Google Scholar 

Mustanski B, Ryan DT, Spinelli MA, Gandhi M, Newcomb ME. Urine point-of-care tenofovir test demonstrates strong predictive clinical and research utility. AIDS. 2023;37(15):2381–7. https://doi.org/10.1097/QAD.0000000000003710.

Article  CAS  PubMed  Google Scholar 

Olanrewaju AO, Sullivan BP, Zhang JY, Bender AT, Sevenler D, Lo TJ, et al. Enzymatic assay for rapid measurement of antiretroviral drug levels. ACS Sens. 2020;5(4):952–9. https://doi.org/10.1021/ACSSENSORS.9B02198.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Olanrewaju AO, Sullivan BP, Bardon AR, Lo TJ, Cressey TR, Posner JD, et al. Pilot evaluation of an enzymatic assay for rapid measurement of antiretroviral drug concentrations. Virol J. 2021;18(1):77. https://doi.org/10.1186/s12985-021-01543-x.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Olanrewaju AO, Sullivan BP, Gim AH, Craig CA, Sevenler D, Bender AT, et al. REverSe TRanscrIptase chain termination (RESTRICT) for selective measurement of nucleotide analogs used in HIV care and prevention. Bioeng Transl Med. 2023;8(1):e10369. https://doi.org/10.1002/BTM2.10369.

Article  CAS  PubMed  Google Scholar 

Cabenuva FDA Prescribing Information. FDA. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/212888s005s006lbl.pdf. Accessed 12 Aug 2024.

Dapivirine vaginal ring 25 mg: European Medicines Agency Public Assessment Report. https://www.ema.europa.eu/en/documents/outside-eu-assessment-report/dapivirine-vaginal-ring-25-mg-public-assessment-report_en.pdf. Accessed 28 Dec 2023.

ANRS-MIE – AC43 Pharmacologic and Resistance groups. Recommendations for Therapeutic Drug Monitoring of CABOTEGRAVIR and RILPIVIRINE during long-acting injectable administration of Vocabria®/Rekambys® every 2 months in HIV-infected patients. Report No.: v2. https://hivfrenchresistance.org/hiv-french-resitance-pharmacology/. Accessed 1 Jul 2022.

Yang H, Chu L, Wu Y, Wang W, Yang J, Zhang Q, et al. LC-MS/MS quantification of nevirapine and its metabolites in hair for assessing long-term adherence. Molecules. 2020;25(23):5692. https://doi.org/10.3390/molecules25235692.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Srivastava P, Moorthy GS, Gross R, Barrett JS. A sensitive and selective liquid chromatography/tandem mass spectrometry method for quantitative analysis of efavirenz in human plasma. PLoS One. 2013;8(6):e63305. https://doi.org/10.1371/journal.pone.0063305.

Article  CAS  PubMed  PubMed Central